The albumin–peptide fusion product, Albiglutide (Tanzeum®), is a recombinant fusion protein with two tandem copies of modified human GLP fused to albumin that was approved to improve glycemic control with adults with type 2 diabetes mellitus. This evidence concerns the gene ALB and type 2 diabetes mellitus.